Lates News

Yaoxian Modern Announces that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for the approval of Azithromycin tablets and Theophylline injection through generic drug quality and efficacy consistency evaluation. Azithromycin tablets are used for infections caused by sensitive bacteria, with sales of 685 million yuan in 2024 in national public medical institutions and urban pharmacies. Theophylline injection is used for the treatment of bronchial asthma, with sales of 135 million yuan in 2024 in national public medical institutions. This consistency evaluation is conducive to product market expansion and sales.